Real-world treatment outcomes and healthcare resource use associated with antiemetics among cancer patients on highly emetogenic platinum-based chemotherapy.

Abstract

Listen

Translate article

e24109 Background: Chemotherapy-induced nausea and vomiting (CINV) is a recognized adverse outcome among cancer patients, and guidelines recommend appropriate prophylactic antiemetics. Highly emetogenic chemotherapy (HEC) is associated with high risk of CINV that potentially lead to additional healthcare resource use. This retrospective study aimed to quantify the treatment outcomes and resource utilization associated with antiemetic use to prevent CINV in a broad US population. Methods: Cancer patients who received platinum–based HEC were identified in the All Payers Claims Database (APCD). The APCD is a database representing the US population with commercial, Medicare, or Medicaid insurance. Insurance claims denote medical care associated with payment, providing an optimal data source to study healthcare resource use. Study patients were age ≥18 years and administered IV 1) fosnetupitant/palonosetron (IV NEPA), 2) aprepitant/fosaprepitant + palonosetron (IV APPA) or 3) aprepitant/fosaprepitant + ondansetron (IV APON) along with HEC. Patients were identified from 1/2016 - 12/2019. The index date was the first treatment date of a study antiemetic. Demographic and clinical characteristics were evaluated in the baseline period, which was 12 months prior to the index date. The post-HEC follow-up period was 14 days, starting the day after each HEC administration. Outcomes were reported descriptively as weighted means, with the cycles of treatment as the unit of analysis, including nausea & vomiting, dehydration, fluid-electrolyte imbalances, and hydration therapy. Results: Study included 1,216 IV NEPA, 43,537 IV APPA, and 16,140 IV APON patients who received HEC. During the post-HEC follow-up period, IV NEPA patients reported fewer occurrences of nausea & vomiting and fluid-electrolyte imbalances per cycle of treatment when compared to IV APPA and IV APON patients. Despite having similar or more dehydration claims for IV NEPA, the occurrence of hydration therapy was lower or similar to the other study groups. (Table). Conclusions: The choice of antiemetics to prevent CINV among cancer patients receiving HEC may impact real-world outcomes and healthcare resource use.[Table: see text]